GET THE LATEST UPDATES
Receive the latest event information about key speakers, sponsorship opportunities and exhibiting.
November 9-11, 2020 | Virtual Conference
Bob retired from Lachman Consultants at the end of 2012 as Executive Vice President and is currently Senior Advisor and Outside Director to the Board at Lachman where he provides support and counsel to the Lachman regulatory team and other Lachman practice areas and also provides regulatory services for the industry. In addition in July of 2014 he accepted the position of President and Chief Scientific Officer of Melbourne Laboratories, a drug development firm. Formerly, Mr. Pollock was the Acting Deputy Director of the Office of Generic Drugs (OGD), Center for Drug Evaluation and Research, Food and Drug Administration. Bob was in the generic drugs program shortly after the passage of the Drug Price Competition and Patent Term Restoration Act (Waxman-Hatch Act). Prior to transferring to the FDA in 1985, he held various field and headquarters assignments with the Health Resources and Services Administration of the Public Health Service. He retired from the PHS in January 1995 with over 20 years of service at the rank of Captain. Mr. Pollock received his B.S. degree in pharmacy and his M.S degree in pharmacy administration at the University of Rhode Island where he studied as a Fellow of the American Foundation for Pharmaceutical Education. Mr. Pollock has numerous publications and presents extensively on the drug approval process as well as issues regarding strategic alliances.